ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Circulating tumor DNA analysis of EGFR -mutant non-small cell lung cancer patients receiving osimertinib following previous tyrosine kinase inhibitor treatment

Jamie J. Beagan; Sander Bach; Robert A. van Boerdonk; Erik van Dijk; Erik Thunnissen; Daan van den Broek; Janneke Weiss; Geert Kazemier; D Michiel Pegtel; Idris Bahce; Bauke Ylstra; Daniëlle A.M. Heideman
Lung Cancer2020DOI: 10.1016/j.lungcan.2020.04.039
6被引13阅读
引用收藏
分享

摘要

ObjectivesCirculating tumor (ct)DNA analysis is rapidly gaining acceptance as a diagnostic tool to guide clinical management of advanced non-small cell lung cancer (NSCLC). Clinically-actionable EGFR mutations can be detected in ctDNA before or after first-line EGFR-Tyrosine Kinase Inhibitor (TKI) treatment, but data are limited for patients with a complex treatment history. This study aimed to explore the feasibility of ctDNA testing in a clinical setting of NSCLC patients receiving osimertinib as a second or third line EGFR-TKI.Materials and MethodsTwenty EGFR T790M-positive NSCLC patients, who had received osimertinib as a second or third line EGFR-TKI and had donated blood samples while attending routine follow-up consultations between April and November 2016, were retrospectively selected to test plasma cfDNA for tumor-guided EGFR mutations. We used EGFR mutations previously identified in tumor-tissue to retrospectively test plasma ctDNA from 20 patients who had received osimertinib as a second or third line EGFR-TKI. Both EGFR-TKI sensitising and T790 M resistance mutations were analysed by droplet digital PCR (ddPCR) in plasma taken alongside routine consultations and ctDNA detection was correlated with response under osimertinib. Follow-up solid-tissue biopsies were obtained after disease progression.ResultsCtDNA was detected under osimertinib treatment in four out of the eight patients (50 %) who showed no response, two out of the seven (29 %) who showed an initial response and none of the five patients (0 %) who showed an ongoing response. The fraction of EGFR -mutant ctDNA in plasma tended to be higher in non-responders (0.1–68 %), compared to the initial responders (0.2–1.1 %). Blood samples were donated up to 34, 27 and 49 weeks after the start of osimertinib for the non-, initial and ongoing responders, respectively.ConclusionsThese findings support a potential role for ctDNA analysis in response monitoring of NSCLC patients with a complex EGFR-TKI treatment history. The weak trend between ctDNA detection and disease progression warrants larger studies to further investigate potential clinical utility.

学科与关键词

关键词
Circulating tumor DNANSCLCEGFRMonitoringOsimertinibEGFR-TKI
相关
加载中…
  • Clearing of circulating tumour DNA predicts clinical response to osimertinib in EGFR mutated lung cancer patients
    Eva Boysen Fynboe Ebert; Tine McCulloch; Karin Holmskov Hansen; Hanne Linnet; Boe Sorensen; Peter Meldgaard2020.
  • Serial plasma cell-free circulating tumor DNA tests identify genomic alterations for early prediction of osimertinib treatment outcome in EGFR T790M-positive non-small cell lung cancer
    Bin-Chi Liao; Wei-Hsun Hsu; Jih-Hsiang Lee; Ching-Yao Yang; Tzu-Hsiu Tsai; Wei-Yu Liao; Chao-Chi Ho; Chia-Chi Lin; Jin-Yuan Shih; Chong-Jen Yu; Ross A. Soo; James Chih-Hsin YangJTO Clinical and Research Reports, 2020, 100099.
  • Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor–positive non-small cell lung cancer who might benefit from sequential tyrosine kinase inhibitor treatment
    Provencio Mariano; Serna-Blasco Roberto; Franco Fabio; Calvo Virgina; Royuela Ana; Auglytė Milda; Sánchez-Hernández Alfredo; de Julián Campayo María; García-Girón Carlos; Dómine Manuel; Blasco Ana; Sánchez José M.; Oramas Juana; Bosch-Barrera Joaquim; Sala María Á.; Sereno María; Ortega Ana L.; Chara Luis; Hernández Berta; Padilla Airam; Coves Juan; Blanco Remedios; Balsalobre José; Mielgo Xabier; Bueno Coralia; Jantus-Lewintre Eloisa; Molina-Vila Miguel Á.; Romero AtochaEuropean Journal of Cancer, 2021, 149.
查看全部 →

发表信息

论文状态
公开发表
期刊
Lung Cancer
发表日期
2020
卷期
第 145 卷
页码
173-180
DOI
10.1016/j.lungcan.2020.04.039
成果收录
CHINAJOURNAL

作者

  • J

    Jamie J. Beagan (第一作者)

  • S

    Sander Bach

查看全部 12 位作者收起作者
  • R

    Robert A. van Boerdonk

  • E

    Erik van Dijk

  • E

    Erik Thunnissen

  • D

    Daan van den Broek

  • J

    Janneke Weiss

  • G

    Geert Kazemier

  • D

    D Michiel Pegtel

  • I

    Idris Bahce

  • B

    Bauke Ylstra

  • D

    Daniëlle A.M. Heideman

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417